Three Years On: What Real-World Data Shows About the MiniMed 780G System in Children

Automated insulin delivery systems are designed to reduce the burden of managing Type 1 diabetes while helping people achieve healthier blood sugar levels. For children and adolescents, early control of blood sugar can make a real difference—both in preventing long-term complications and in reducing the mental load of constant diabetes management.

Most studies of these systems take place in controlled clinical settings. This new research is different: it looks at real-world data from nearly 1,700 children who used the MiniMed 780G system between 2020 and 2025, tracked over three full years. Understanding how the technology performs in everyday life—not just in a research center—helps families and clinicians know what to expect.

When children started using the MiniMed 780G's automated features (called advanced hybrid closed loop, or AHCL), their time in range improved quickly. Before automation, children spent about 64% of the time in their target blood sugar range (70–180 mg/dL). By one month into using the system, this had jumped to 73.6%—and it stayed at that level three years later.

The system also improved time spent in a tighter range (70–140 mg/dL), raising it to about 52% within the first month. This tight range stayed stable throughout the study, meaning children weren't seeing improvements slip away over time.

Low blood sugar events—a concern with any insulin therapy—remained low even as the system took on more and more of the insulin-dosing responsibility automatically.

One key finding was how the system adapted as children grew. As kids entered their teenage years, they naturally entered more carbohydrates into the system. Despite this increase in carb counting—which might seem like it could worsen blood sugar control—the system maintained its performance, continuing to deliver insulin both automatically and in response to what kids reported eating.

The proportion of insulin delivered automatically by the system increased over the three-year period, yet the system kept low blood sugar episodes in check. This suggests the automation became more reliable and was handling more of the diabetes management work as families became more comfortable with the technology.

This real-world study offers reassurance that the MiniMed 780G can deliver sustained benefits over years, not just weeks or months. The improvements in time in range appeared immediately and held steady, suggesting the system doesn't lose effectiveness over time.

The data also shows that as children grow and their diabetes management needs evolve, the system can adapt and continue performing well. For families considering automated insulin delivery, this three-year evidence base represents important information to discuss with your diabetes care team.

Source: Hormone research in paediatrics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.